Ocera Therapeutics (OCRX) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
March 11, 2015 4:01 PM EDTPALO ALTO, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced updates to its clinical development programs and reported financial results and other business highlights for the quarter and year ended December 31, 2014.
"2014 was a transformational year for Ocera," said Linda Grais, M.D., chief executive officer of Ocera. "We completed a $25 million gross financing, strengthened our management team and Board of Directors, initiated enrollment in our "STOP-HE" Phase 2b trial of OCR-002 in patients with acute hepatic... More
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
March 11, 2015 4:01 PM EDTPALO ALTO, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced updates to its clinical development programs and reported financial results and other business highlights for the quarter and year ended December 31, 2014.
"2014 was a transformational year for Ocera," said Linda Grais, M.D., chief executive officer of Ocera. "We completed a $25 million gross financing, strengthened our management team and Board of Directors, initiated enrollment in our "STOP-HE" Phase 2b trial of OCR-002 in patients with acute hepatic... More
